title: Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009-2013.
abstract: Objectives Squamous cell carcinoma (SCC) is the most common oral tumor in cats and typically carries a poor prognosis with current treatment options. The objective of this study was to evaluate the toxicity of toceranib phosphate (Palladia; Pfizer) in cats with oral SCC in combination with other treatment modalities. Methods In this study, 35 cats were retrospectively evaluated to determine toxicity when treated with toceranib in combination with other treatment modalities. Cats received toceranib at a median dose of 2.75 mg/kg (range 1.9-4.17 mg/kg) 3 days a week. Cats also underwent additional therapies, including surgical excision, radiation therapy, chemotherapy and/or use of non-steroidal anti-inflammatory drugs. Results Toxicity was seen in six cats, with five cases of grade 1 or 2 gastrointestinal (GI) toxicity and one grade 4 metabolic toxicity. Toceranib was discontinued in one cat and two cats received dose reductions. None of the cats required treatment delays or hospitalization due to toxicity. Median toceranib treatment duration was 77 days (range 7-741 days). Conclusions and relevance This study revealed that toceranib was well tolerated by the majority of cats, with five cases of low-grade GI toxicity and one case of metabolic toxicity. Given the favorable toxicity profile, future studies further evaluating the safety and efficacy of toceranib for cats with oral SCC should be considered.
authors.affiliation: 1 Central Hospital for Veterinary Medicine, North Haven, CT, USA.
authors.forename: Gina A
authors.initials: GA
authors.lastname: Olmsted
authors.affiliation: 2 The Veterinary Cancer Center, Norwalk, CT, USA.
authors.forename: John
authors.initials: J
authors.lastname: Farrelly
authors.affiliation: 2 The Veterinary Cancer Center, Norwalk, CT, USA.
authors.forename: Gerald S
authors.initials: GS
authors.lastname: Post
authors.affiliation: 3 Chicago Veterinary Specialty Group, Chicago, IL, USA.
authors.forename: Jaclyn
authors.initials: J
authors.lastname: Smith
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000662:veterinary*; D002371:Cat Diseases / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002415:Cats; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014481:United States
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; C464577:toceranib phosphate